OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
A Phase III, Multi-center, Randomized, Single-blind (to Evaluator), Parallel, and Positive-controlled Clinical Trial Evaluating the Efficacy and Safety of OPC-1085EL Ophthalmic Solution in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The trial includes 2 period:
- Screening period: 4 weeks. For subjects entering the screening period, 0.005% latanoprost will be administered for 4 consecutive weeks, one drop for each eye, once per day.
- Evaluation period: 8 weeks. Subjects who are eligible are randomly assigned to the OPC-1085EL group or 0.005% latanoprost group at a ratio of 1:1, one drop for each eye, once per day.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Xinghuai Sun, PHD
- Phone Number: 18917761818
- Email: xhsun@shmu.edu/cn
Study Contact Backup
- Name: Kaidi Wang, PHD
Study Locations
-
-
-
Shanghai, China
- Eye & ENT Hospital of Fudan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Gender: Unlimited
- Hospitalization status: Outpatients
- Age: 20-80 years old
Subjects with both eyes diagnosed as primary open angle glaucoma or ocular hypertension.
[At the end of the screening period]
- IOP: After 4 weeks treatment with 0.005% latanoprost, the unilateral eye with a pre-dose IOP from 18 mmHg to <30 mmHg, and IOP <30 mmHg in the contralateral eye.
Exclusion Criteria:
- Subjects with a best-corrected visual acuity ≤ 0.2.
- Subject with any secondary glaucoma such as exfoliative or pigmented glaucoma.
- Subjects who cannot stop using contact lenses during the trial.
- Subjects who are judged by investigators to be at risk when receiving carteolol hydrochloride or 0.005% latanoprost as monotherapy.
- Subjects who are allergic to any ingredients in carteolol or latanoprost.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: subject receive OPC-1085EL solution
OPC-1085EL group ,one drop for each eye, once per day for 8 weeks
|
one drop for each eye, once per day
Other Names:
|
|
Active Comparator: subject receive 0.005% latanoprost ophthalmic solution
0.005% latanoprost ophthalmic solution group ,one drop for each eye, once per day for 8 weeks
|
one drop for each eye, once per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluate pre-dose intraocular pressure change from baseline to week 8
Time Frame: baseline;week 8
|
Baseline intraocular pressure: The pre-dose and 2 hours after dosing intraocular pressures measured
|
baseline;week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety evaluation variable:adverse event
Time Frame: from screening period to evaluation period, assessed up to 3 weeks.
|
adverse event start date, end date, seriousness, severity, relationship to trial treatment (IMP causality), action taken with trial treatment, and outcome will be collect.
|
from screening period to evaluation period, assessed up to 3 weeks.
|
|
intraocular pressure change rate from baseline
Time Frame: week 4:
|
intraocular pressure change rate=(intraocular pressure change from baseline at each time point)/ (corresponding baseline intraocular pressure) × 100%
|
week 4:
|
|
intraocular pressure
Time Frame: Week 4;Week 8:
|
evaluate the effects of OPC-1085ELv.s.0.005% latanoprost by measure intraocular pressure
|
Week 4;Week 8:
|
|
intraocular pressure change from baseline
Time Frame: Week 4;Week 8
|
evaluate the effects of OPC-1085ELv.s.0.005% latanoprost by measure intraocular pressure
|
Week 4;Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Huaixing Sun, Doctor, Eye & ENT Hospital of Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Eye Diseases
- Hypertension
- Glaucoma
- Glaucoma, Open-Angle
- Ocular Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Anti-Arrhythmia Agents
- Adrenergic Agents
- Antihypertensive Agents
- Sympatholytics
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Latanoprost
- Pharmaceutical Solutions
- Ophthalmic Solutions
- Carteolol
Other Study ID Numbers
Other Study ID Numbers
- 001-403-00013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.